Sutro Biopharma (STRO) Cash & Equivalents Growth (1y) (2018 - 2025)
Sutro Biopharma (STRO) Cash & Equivalents Growth (1y) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - | 23.81% |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | 15.53% |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn | 90.42% |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn | 17.50% |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn | -4.13% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 71.81% |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 67.78% |
| 10 | Sutro Biopharma | 206.03 Mn | 64.60 Mn | - | -69.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -69.45% |
| Sep 30, 2025 | -62.24% |
| Jun 30, 2025 | -29.48% |
| Mar 31, 2025 | 62.88% |
| Dec 31, 2024 | 174.74% |
| Sep 30, 2024 | 113.33% |
| Jun 30, 2024 | -61.38% |
| Mar 31, 2024 | 4.40% |
| Dec 31, 2023 | 46.59% |
| Sep 30, 2023 | -15.44% |
| Jun 30, 2023 | 197.16% |
| Mar 31, 2023 | 116.16% |
| Dec 31, 2022 | 55.37% |
| Sep 30, 2022 | 215.17% |
| Jun 30, 2022 | 40.29% |
| Mar 31, 2022 | -48.22% |
| Dec 31, 2021 | -85.25% |
| Sep 30, 2021 | -52.30% |
| Jun 30, 2021 | -13.71% |
| Mar 31, 2021 | 28.13% |